Twice-weekly high-dose rHuEpo for the treatment of anemia in patients with low-risk myelodysplastic syndromes

Acta Haematol. 2008;120(2):104-7. doi: 10.1159/000166864. Epub 2008 Oct 31.
No abstract available

Publication types

  • Clinical Trial, Phase II

MeSH terms

  • Aged
  • Aged, 80 and over
  • Anemia / drug therapy*
  • Cytogenetic Analysis
  • Erythropoietin / administration & dosage*
  • Erythropoietin / toxicity
  • Female
  • Hemoglobins
  • Humans
  • Male
  • Middle Aged
  • Myelodysplastic Syndromes / complications*
  • Myelodysplastic Syndromes / drug therapy
  • Recombinant Proteins
  • Treatment Outcome

Substances

  • Hemoglobins
  • Recombinant Proteins
  • Erythropoietin